Andrew Vito
@andrew_vito
Followers
764
Following
17K
Media
10
Statuses
1K
https://t.co/nmh9p1yFnu. Business inquiries: @breadyathletes
Joined July 2013
Made it to the playoffs but fell short of the goal. Excited to put a year of varsity football under my belt as a freshman. Now the real work begins, when no one is watching! Season Stats: Team Lead - 93 total tackles 43 Solo/12 TFLs/2 FF/2FR @MustangsFBall @HSSportsNJ @NJFCA
hudl.com
2025 Full Season Highlights
0
2
4
Closed the regular season with a W! 💪 ⚡️2TDs, 1 INT - on to the playoffs! 📽️Clips courtesy of @bigstatesports
@MustangsFBall @JoeMento @Coach_Espo @BrendanScoutsNJ @PrepRedzoneNJ @HSSportsNJ @nj_athletics @njgridiron_ @AllinonHSSports @ONNJSports @dailyrecordspts @donohugel
0
5
14
Meet the 'consiglieri' behind the rise of Bergen Catholic football | Cooper
northjersey.com
Bergen Catholic's assistant head coach is also the trendsetter, the problem-solver and the sounding board. He might be the secret to their success.
0
4
13
First 3 games. 📽️ - Off. (WR): 18 rec., 270 yds., 3 TDs - Def. (CB): 18 tackles, 2 INTS - S.T. (KR): 4 returns, 88 yards Just getting started! Roll 'Stangs! 👊🐎 https://t.co/ma93SIYmFw
@MustangsFBall @JoeMento @Coach_Espo @BrendanScoutsNJ @PrepRedzoneNJ @deech07
hudl.com
First 3 Games - 2025 Season
0
3
8
Congrats @AndreaNecchi @siadaneshmand @MichvdHeijden entire SunRISe-1 team on this BIG step forward for patients with BCG-unresponsive NMIBC!
Important news for our patients following the @JCO_ASCO publication of #SunRIse1 primary results @ASCO @IBCG_BladderCA @AssPalinuro @BladderCancerUS @WorldBladderCan @SanRaffaeleMI @MyUniSR
https://t.co/DaZPbiXC8a
1
3
23
JUST IN: Tar200 now @US_FDA approved based on SunRise-1 phase 2 trial in BCG unresponsive NMIBC. -Intravesical form of Gemcitabine - CR: 82.4%/grade ≥3 AE 12.9% - DFS 70.2% at 12m - 51% of CRs with DOR ≥ 12 months.
3
66
186
Intravesical Gemcitabine via TAR200 for BCG - unresponsive NMIBC with CIS +/- papillary tumors is FDA approved. It joins a number of other agents with a spectrum of MOAs. With data generated from single arm trials there is not a clear winner.
6
63
162
Wasn’t able to capture every moment, however, managed to get a few. Looking forward to watching Nick Palumbo in the years to come. 🙏
1
1
2
Great time competing with my teammates @MustangsFBall at the @WayneValleyFB 7v7 Shootout yesterday! The seperation is in the preparation! @MustangsFBall @Mad_Qb @JoeMento @brett_kunkel8 @BrendanScoutsNJ @DantePalladino2 @lukeguilbert56 @joeybeyer @rickybeyer33 @RyanConlon23
0
6
10
The 4th live Uromigos meeting is happening on 7th & 8th Nov ‘25 in Nashville. It’s going to have an international flavour with America’s 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇮🇳 🇦🇺 🇪🇺 Uromigos Cup competition (details to follow). Sessions ranging from ADCs in MIBC to the changing shape of
0
16
46
It’s no NFL or College Football but amazing things are happening in the CFL
154
419
13K
🚨 New episode alert! Listen in on some of the breakthroughs and progress discussed this year during ASCO 2025. In this episode, Dr. Michiel Van Der Heijden joins the Uromigos to discuss the ipilimumab + nivolumab vs. chemotherapy randomization in this trial from his ASCO 2025
1
6
15
❗️ This just in: The @US_FDA has approved the use of #darolutamide for the treatment of metastatic #prostatecancer: https://t.co/p97zLgUwUZ 👉 The approval is based on positive results of the ARANOTE study, which compared darolutamide with placebo in patients with metastatic
0
1
2
I had a great time competing at the AVC Mega Football Camp at Kean University yesterday. I Appreciate all the coaches Thank you!! @CoachAVC_FDU @MustangsFBall @Mad_Qb @JoeMento
0
3
15
#FDA approves darolutamide for metastatic castration-sensitive #prostatecancer
@US_FDA @ASCO @APCCC_Lugano @OncoAlert #ASCO25 @Uromigos @OncBrothers
2
33
102
Just in time as Darolutamide is now also @US_FDA approved for mHSPC based off ARANOTE study - Ph III, metastatic (by bone scan or CT/MRI) hormone-sensitive prostate cancer. - rPFS NR (statistically significant) but OS (not statistically significant) #OncTwitter #MedTwitter
🗣️Prostate Oral Abstract #ASCO25 👉Abst5004: Dr @CaPsurvivorship presenting #HRQoL w/ darolutamide on #ARANOTE 📈HRQoL assessed by: - FACT-P: Funct Assessmt of Cancer Therapy–Prostate - BPI-SF: Brief Pain Inventory–Short Form
2
25
73
AMPLITUDE trial #ASCO25 @AttardLab @OncoAlert increases rPFS for niraparib (PARPi) + ARPI (Abi) in mCSPC with + BRCA/HRR (HR-0.53/0.63) & a trend toward improved OS (HR0.75/0.79). This moves PARPi into 1st line and supports personalised approaches in 1st line RCC
0
46
103
🚨 New episode alert! @Silke_Gillessen and @ChrisSweens1 join us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Expect some interesting themes and insights. 🎙️ GU Oncology Now: https://t.co/ZlJRGfFpyF 🍎
0
12
35
Excellent team win. Nutley 3 West Orange 0. First home run of the year for Nick Palumbo.
1
2
4
🚨 New episode alert! Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well. 🎙️ GU Oncology Now: https://t.co/FggMXsvNyf 🍎 Apple Podcasts:
0
6
11